26.49
2.32%
+0.60
After Hours:
26.44
-0.05
-0.19%
Anika Therapeutics Inc. stock is currently priced at $26.49, with a 24-hour trading volume of 71,004.
It has seen a +2.32% increased in the last 24 hours and a +3.07% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $25.88 pivot point. If it approaches the $26.58 resistance level, significant changes may occur.
Previous Close:
$25.89
Open:
$25.96
24h Volume:
71,004
Market Cap:
$392.81M
Revenue:
$166.66M
Net Income/Loss:
$-82.67M
P/E Ratio:
-17.31
EPS:
-1.53
Net Cash Flow:
$-7.22M
1W Performance:
+2.28%
1M Performance:
+3.07%
6M Performance:
+34.67%
1Y Performance:
+1.88%
Anika Therapeutics Inc. Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc.
Sector
Industry
Phone
781-457-9000
Address
32 Wiggins Avenue, Bedford, MA
Anika Therapeutics Inc. Stock (ANIK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Oct-14-22 | Resumed | Stephens | Equal-Weight |
Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
Nov-16-21 | Initiated | Stephens | Overweight |
Jul-16-21 | Initiated | UBS | Neutral |
Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Nov-05-19 | Initiated | BWS Financial | Sell |
Sep-24-19 | Reiterated | Barrington Research | Outperform |
Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
Oct-27-17 | Reiterated | Barrington Research | Outperform |
May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc. Stock (ANIK) Latest News
Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
Zacks Investment Research
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
GlobeNewswire Inc.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
Zacks Investment Research
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
GlobeNewswire Inc.
Anika Therapeutics Inc. Stock (ANIK) Financials Data
Anika Therapeutics Inc. (ANIK) Revenue 2024
ANIK reported a revenue (TTM) of $166.66 million for the quarter ending December 31, 2023, a +6.67% rise year-over-year.
Anika Therapeutics Inc. (ANIK) Net Income 2024
ANIK net income (TTM) was -$82.67 million for the quarter ending December 31, 2023, a -456.34% decrease year-over-year.
Anika Therapeutics Inc. (ANIK) Cash Flow 2024
ANIK recorded a free cash flow (TTM) of -$7.21 million for the quarter ending December 31, 2023, a -134.48% decrease year-over-year.
Anika Therapeutics Inc. (ANIK) Earnings per Share 2024
ANIK earnings per share (TTM) was -$5.65 for the quarter ending December 31, 2023, a -448.54% decline year-over-year.
About Anika Therapeutics Inc.
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Cap:
|
Volume (24h):